A Big Bonus from a Cholesterol-Buster?

A class of blockbuster drugs known as statins could have a wealth of welcome side effects on maladies ranging from stroke to osteoporosis

When Mevacor, the first of a new class of cholesterol-lowering drugs known as statins, hit the market in 1987, doctors and patients were elated. Unlike other drugs available at the time, Mevacor was effective, had only minor but unpleasant side effects, and best of all, could be taken orally once a day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.